Viloxazine hydrochloride


Entry
D02572                      Drug                                   
Name
Viloxazine hydrochloride (USAN);
Qelbree (TN);
Vivalan (TN)
Product
QELBREE (Supernus Pharmaceuticals)
Formula
C13H19NO3. HCl
Exact mass
273.1132
Mol weight
273.7558
Structure
Simcomp
Class
Neuropsychiatric agent
 DG03085  Selective norepinephrine reuptake inhibitor (NRI)
Metabolizing enzyme substrate
 DG01644  CYP2D6 substrate
 DG02924  UGT substrate
  DG03188  UGT1A9 substrate
  DG03187  UGT2B15 substrate
Remark
ATC code: N06AX09
Chemical structure group: DG00956
Product (DG00956): D02572<US>
Efficacy
Antidepressant, Selective noradrenaline reuptake inhibitor (NRI)
  Disease
Attention deficit hyperactivity disorder [DS:H01895]
Target
SLC6A2 (NAT1) [HSA:6530] [KO:K05035]
  Pathway
hsa04721  Synaptic vesicle cycle
Metabolism
Enzyme: CYP2D6 [HSA:1565], UGT1A9 [HSA:54600], UGT2B15 [HSA:7366]
Interaction
Structure map
map07027  Antidepressants
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 N NERVOUS SYSTEM
  N06 PSYCHOANALEPTICS
   N06A ANTIDEPRESSANTS
    N06AX Other antidepressants
     N06AX09 Viloxazine
      D02572  Viloxazine hydrochloride (USAN) <US>
USP drug classification [BR:br08302]
 Central Nervous System Agents
  Attention Deficit Hyperactivity Disorder Agents, Non-amphetamines
   Viloxazine
    D02572  Viloxazine hydrochloride (USAN)
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG03085  Selective norepinephrine reuptake inhibitor (NRI)
   DG00956  Viloxazine
    D02572  Viloxazine hydrochloride
 Metabolizing enzyme substrate
  DG01644  CYP2D6 substrate
   DG00956  Viloxazine
    D02572  Viloxazine hydrochloride
  DG02924  UGT substrate
   DG03188  UGT1A9 substrate
    DG00956  Viloxazine
     D02572  Viloxazine hydrochloride
   DG03187  UGT2B15 substrate
    DG00956  Viloxazine
     D02572  Viloxazine hydrochloride
Target-based classification of drugs [BR:br08310]
 Transporters
  Solute carrier family
   SLC6
    SLC6A2 (NAT1)
     D02572  Viloxazine hydrochloride (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D02572
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D02572
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D02572
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG03085  Selective norepinephrine reuptake inhibitor (NRI)
   DG00956  Viloxazine
 Metabolizing enzyme substrate
  DG01644  CYP2D6 substrate
   DG00956  Viloxazine
  DG02924  UGT substrate
   DG03188  UGT1A9 substrate
    DG00956  Viloxazine
   DG03187  UGT2B15 substrate
    DG00956  Viloxazine
Other DBs
CAS: 35604-67-2
PubChem: 17396743
LigandBox: D02572
NIKKAJI: J262.760D
KCF data

ATOM        18
            1   C8x C    12.6000  -17.0800
            2   C8x C    12.6000  -15.6800
            3   C8x C    13.7900  -14.9800
            4   C8y C    15.0500  -15.6800
            5   C8y C    15.0500  -17.0800
            6   C8x C    13.7900  -17.7800
            7   O2a O    16.2400  -17.7800
            8   C1b C    17.5000  -17.0800
            9   C1y C    18.6900  -17.7800
            10  O2a O    16.2400  -14.9800
            11  C1b C    17.5000  -15.6800
            12  C1a C    18.6900  -14.9800
            13  O2x O    19.8800  -17.0800
            14  C1x C    21.1400  -17.7800
            15  C1x C    21.1400  -19.1800
            16  N1x N    19.8800  -19.8800
            17  C1x C    18.6900  -19.1800
            18  X   Cl   24.7800  -16.6600
BOND        18
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 1
            10    4  10 1
            11   10  11 1
            12   11  12 1
            13    9  13 1
            14   13  14 1
            15   14  15 1
            16   15  16 1
            17   16  17 1
            18    9  17 1